EurekAlert! -
16 Oct 2020 06:00
(NIH/Office of the Director) The National Institutes of Health has launched an adaptive Phase 3 clinical trial to evaluate the safety and efficacy of three immune modulator drugs in hospitalized adults with COVID-19. Some COVID-19 patients experience an immune response in which the immune system unleashes excessive amounts of proteins that trigger inflammation -- called a "cytokine storm" -- that can lead to acute respiratory distress syndrome, multiple organ failure and other life-threatening c...
Share this Article